EA201201362A1 - PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING - Google Patents
PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAININGInfo
- Publication number
- EA201201362A1 EA201201362A1 EA201201362A EA201201362A EA201201362A1 EA 201201362 A1 EA201201362 A1 EA 201201362A1 EA 201201362 A EA201201362 A EA 201201362A EA 201201362 A EA201201362 A EA 201201362A EA 201201362 A1 EA201201362 A1 EA 201201362A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aerosol
- inhibitors
- proteasis
- obtaining
- aerosol composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008249 pharmaceutical aerosol Substances 0.000 title 1
- 239000000443 aerosol Substances 0.000 abstract 3
- 201000004813 Bronchopneumonia Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к медицине и описывает лекарственную композицию водорастворимых белковых или полипептидных соединений из группы ингибиторов протеолитических ферментов для создания аэрозоля с помощью водонерастворимого озонсберегающего пропеллента в аэрозольных устройствах, снабженных дозирующим клапаном. Созданный аэрозольный состав может найти применение при лечении заболеваний, сопровождающихся нарушением протеолитического баланса, таких как респираторные инфекции, включая грипп, кератоконъюнктивиты вирусной и бактериальной этиологии, герпетические поражения слизистых оболочек и кожи, хроническая обструктивная бронхопневмония, астма и др.The invention relates to medicine and describes a medicinal composition of water-soluble protein or polypeptide compounds from the group of proteolytic enzyme inhibitors to create an aerosol using a water-insoluble ozone-saving propellant in aerosol devices equipped with a metering valve. The created aerosol composition can be used in the treatment of diseases accompanied by a violation of the proteolytic balance, such as respiratory infections, including influenza, keratoconjunctivitis of viral and bacterial etiology, herpetic lesions of the mucous membranes and skin, chronic obstructive bronchopneumonia, asthma, etc.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011144624A RU2657523C2 (en) | 2011-11-03 | 2011-11-03 | Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201201362A1 true EA201201362A1 (en) | 2013-05-30 |
| EA034991B1 EA034991B1 (en) | 2020-04-15 |
Family
ID=48192963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201362A EA034991B1 (en) | 2011-11-03 | 2012-10-27 | Pharmaceutical aerosol formulation of a protease inhibitor |
Country Status (4)
| Country | Link |
|---|---|
| EA (1) | EA034991B1 (en) |
| GB (1) | GB2511011A (en) |
| RU (1) | RU2657523C2 (en) |
| WO (1) | WO2013066214A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2711080C2 (en) * | 2015-06-15 | 2020-01-15 | Олег Петрович Жирнов | Combined aerosol composition based on protease inhibitors and preparation thereof |
| US20240415944A1 (en) * | 2021-04-06 | 2024-12-19 | Andrey Alexandrovich Ivashchenko | Aqueous aprotinin-containing antiviral pharmaceutical composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2656944B2 (en) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | Aerosolization of protein therapeutics |
| RU2054180C1 (en) * | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Method and aerosol for treating respiratory virus infections |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US6294153B1 (en) * | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
| JP2003501404A (en) * | 1999-06-04 | 2003-01-14 | デルルックス ファーマシューティカル コーポレイション | Preparation comprising dehydrated particles of drug and method of preparing same |
| WO2002043750A2 (en) * | 2000-12-01 | 2002-06-06 | Battelle Memorial Institute | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| RU2356537C2 (en) * | 2007-07-25 | 2009-05-27 | Закрытое Акционерное Общество (ЗАО) "Пульмомед" | Pharmaceutical composition of metered aerosols containing antiasthmatic agents in form of suspensions, solutions, emulsions, solutions and emulsions |
| RU2425691C1 (en) * | 2010-07-15 | 2011-08-10 | ВАКЕ спол с.р.о. | Aprotinin aerosol for treating viral respiratory infections |
-
2011
- 2011-11-03 RU RU2011144624A patent/RU2657523C2/en not_active Application Discontinuation
-
2012
- 2012-10-27 EA EA201201362A patent/EA034991B1/en not_active IP Right Cessation
- 2012-11-01 GB GB1409877.6A patent/GB2511011A/en not_active Withdrawn
- 2012-11-01 WO PCT/RU2012/000896 patent/WO2013066214A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2657523C2 (en) | 2018-06-14 |
| GB201409877D0 (en) | 2014-07-16 |
| WO2013066214A3 (en) | 2013-08-22 |
| EA034991B1 (en) | 2020-04-15 |
| RU2011144624A (en) | 2013-05-10 |
| WO2013066214A2 (en) | 2013-05-10 |
| GB2511011A (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| BR112015007366A2 (en) | acylaminopyrimidine derivatives for the treatment of viral infections and other diseases | |
| BR112014007223A2 (en) | estra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments | |
| HK1223301A1 (en) | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy | |
| EA201690541A1 (en) | DRY POWDER PREPARATION CONTAINING PHOSPHODESTERASE INHIBITOR | |
| CL2014000122A1 (en) | Compounds derived from indazole, janus kinase inhibitors (jak); pharmaceutical composition that includes them; and its use to treat allergic rhinitis, nasal congestion, asthma, chronic bronchitis, arthritis, heart failure, ulcerative colitis, viral and bacterial infection, cancer and Alzheimer's, among other diseases. | |
| EP4620525A3 (en) | Methods and compositions for treatment of pulmonary hypertension and other lung disorders | |
| WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
| BR112014015845A2 (en) | azetidine derivatives, pharmaceutical compositions and their use | |
| JP2015534562A5 (en) | ||
| PH12020551709A1 (en) | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | |
| CN111936124A (en) | Aerosol pharmaceutical composition containing glycopyrronium salt and indacaterol salt, and preparation method and application thereof | |
| MX377175B (en) | TIOTROPIUM INHALATION SOLUTION, ADMINISTERED IN NEBULIZED FORM AND ITS USE TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | |
| BR112014011345A2 (en) | influenza virus-like particles (vlps) comprising nicotiana tabacum produced by hemagglutinin | |
| PH12018502522A1 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
| NZ631105A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| BR112014005538A2 (en) | aqueous compositions comprising arbecacin | |
| EA201591415A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY | |
| WO2015049519A3 (en) | Method and apparatus for making compositions for pulmonary administration | |
| EA201201362A1 (en) | PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING | |
| EA201201393A1 (en) | INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER | |
| BR112015028890A2 (en) | Pyridone derivatives for the treatment of viral infections and other diseases | |
| MX2018013475A (en) | Carboxylic acid for treating/preventing nasal congestion. | |
| BR112014007491A2 (en) | amino acid sequences for pathogen control | |
| EA201500486A1 (en) | PHARMACEUTICAL COMPOSITION FOR AEROSOL APPLICATION AND ITS PREPARATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): TJ TM |